Keywords: memory/roche, mem, enters, schizophrenia, biomarker, study, usa

Memory/Roche's MEM 3454 enters schizophrenia biomarker study

Article | 25 February 2008

Print This

The USA's Memory Pharmaceuticals plans to conduct a clinical study of MEM 3454, its lead nicotinic alpha-7 partial agonist, on two ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in